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Obesity and the Dysregulation of Fatty Acid Metabolism: 
Implications for Healthy Aging
Introduction. The population of the world is aging. In 2010, an estimated 524 million people
were aged 65 years or older presenting eight percent of the global population. By 2050, this
number is expected to nearly triple to approximately 1.5 billion, 16 percent of the world’s
population.  Although  people  are  living  longer,  the  quality  of  their  lives  are  often
compromised due to ill-health. 
Areas  covered.  Of the  conditions  which  compromise  health  as  we age,  obesity  is  at  the
forefront.  Over  half  of  the  global  older  population  were  overweight  or  obese  in  2010,
significantly  increasing  the  risk  of  a  range  of  metabolic  diseases.  Although,  it  is  well
recognised excessive calorie intake is a fundamental driver of adipose tissue dysfunction, the
relationship between obesity; intrinsic aging; and fat metabolism is less understood. In this
review we discuss the intersection between obesity, aging and the factors which contribute to
the dysregulation of whole-body fat metabolism. 
Expert  Commentary.  Being obese disrupts an array of physiological  systems and there is
significant crosstalk among these. Moreover it is imperative to acknowledge the contribution
intrinsic aging makes to the dysregulation of these systems and the onset of disease. 
Keywords: Aging, obesity, fatty acid metabolism, inflammaging, endocrine system 
Introduction
The world population is aging[1,2]. However, despite the dramatic rise in life expectancy
global  health  is  on the decline.  Of the clinical  problems whose prevalence  is  increasing,
obesity, a chronic condition which is underpinned by an imbalance between energy ingested
versus energy expended, is the most pronounced. Globally, more than half a billion adults
aged  20  years  and  older  are  obese  (BMI>30kg/m2)  worldwide[3].  In  2014,  39% of  the
world’s adult population were overweight (BMI >25kg/m2), with 13% classed as obese, a
figure which has more than doubled since 1980[3]. This problem is amplified when the data
for England is considered. In England it has been estimated ~80 % of males aged 55-64 years
are overweight/obese, while and ~70% of females aged between 55-64 years are overweight/
obese[4] (Figure 1).
It is projected 2.8 million people die annually as a result of being overweight or obese[3].
These fatalities are underpinned by the pathological footprint left by obesity, characterised by
clinical conditions, which are the direct or indirect result of being overweight or obese. Such
conditions include hypertension[5], insulin resistance[6], cardiovascular disease (CVD)[7],
type-2  diabetes  mellitus  (T2DM)[8],  rheumatoid  arthritis[9],  dementia[10],  and  certain
cancers,  for  example,  breast[11],  colorectal[12],  oesophageal[13],  pancreatic[14] and
gastric[15]. A feature of many of the diseases associated with obesity is the disruption of
whole-body fatty  acid  metabolism;  a  metabolic  system which  is  intimately  coupled  with
adipose tissue function[16]. An elementary summary of the biological mechanisms which
regulate  fat  metabolism  is  presented  in  figure  2.  Briefly,  ingested  lipids  are  packaged
intestinally and released into the blood stream as chylomicrons. Chylomicrons are hydrolysed
by lipoprotein lipase (LPL), releasing free fatty acids (FFAs) into a fatty acid pool. FFAs are
removed from the pool by muscle and hepatic tissue, where they are either oxidized or re-
esterified.  Hepatic  triacylglycerides  (TAGs)  can  be  shuttled  into  the  blood  stream  as  a
constituent of very low density lipoproteins (VLDLs). During periods of fasting, or as a result
of sustained physical activity (PA), hormone sensitive lipase (HSL) is activated, and serves to
mobilize FFAs by hydrolysing TAG found in adipose tissue[16]. Conversely during the fed
state, adipose tissue fat storage is stimulated and fat mobilization suppressed by insulin. The
activity  of  HSL  is  regulated  by  insulin,  via  an  increase  or  decrease  in  the  extent  of
phosphorylation  of  HSL,  depending  on  the  respective  metabolic  state.  Clearly,  the
mechanisms which regulate fat metabolism are interdependent, and subtle alterations to them
can disrupt fat metabolism. For instance, adipose tissue is a key regulatory hub within fat
metabolism and  many  of  the  clinical  manifestations  associated  with  obesity  are  a  direct
consequence of the enlargement of and/or an increase in the number of cells found in adipose
tissue,  which is  the  result  of  excessive  TAG deposition[17].  However,  it  is  important  to
recognise  that  despite  this,  metabolically  healthy  obese  individuals  may  not  have  these
clinical manifestations[18]. 
The anatomical remodeling of adipose tissue results in a pathophysiology, characterised by
the  release  of  excess  FFAs;  a  state  induced  as  a  result  of  enhanced  lipolysis[19].  This
pernicious metabolic state is often associated with immune system dysfunction and increased
hormonal secretion. For instance, T2DM is regularly accompanied by a rise in inflammatory
markers in tandem with hyperinsulinemia[20]. Excess calorie intake is a key driver of adipose
tissue dysfunction and concomitant  metabolic  dysregulation,  however  intrinsic  aging also
contributes  significantly  to  the  dysfunction  of  adipocytes  and  lipid  metabolism  more
broadly[21,22].  In  this  paper  we  will  discuss  the  relationship  between  whole  body  fat
metabolism and the aging process. Our aim is to emphasize the contribution aging has to play
in  disrupting  whole-body fat  metabolism homeostasis  and the  contribution  this  makes  to
health in addition to obesity. 
Dysregulation of Fatty Acid Metabolism with Age
During aging, body fat is redistributed from subcutaneous stores to the muscles and viscera
[23-26]. Redistribution of fat to visceral adipose tissue is associated with a concomitant rise
in plasma FFAs[27]. However, it must be stressed this study was conducted on individuals of
different  ethnicities,  and  therefore,  there  may  be  differences  in  adipose  tissue  metabolic
activity. This is pathophysiologically significant as obesity provokes the release of excess
FFAs. High levels of these fatty acids are the drivers of lipotoxicity, a condition characterised
by  an  increase  in  oxidative  stress  [28].  The  coupling  of  dysregulated  plasma  fatty  acid
metabolism and oxidative stress is an important link connecting fat metabolism to one of the
main theories of biogerontology; the free radical theory of aging. This theory proposes that
the damage which accumulates with time in a biological system is a result of oxidative stress,
and thus accounts for aging  [29,30]. Therefore, an increase in FFAs due to age related fat
redistribution could indirectly be a major contributor to the overall rise in oxidative stress; a
hallmark  of  aging  [31].  Additionally,  lipid  accumulation  within  skeletal  muscle  cells  is
correlated  with insulin  resistance.  Moreover a change in the lipid composition of muscle
tissue has been shown to have a significant impact on fatty acid metabolism, although not all
muscle  fibres  interact  with  fatty  acid  metabolism in  the  same manner[32].  For  instance,
certain studies have found that type 1 muscle fibres have an increased response to insulin
when compared to their less sensitive type II counterparts[33].
Elevated plasma fatty acids also contribute to hypertriglyceridemia by disrupting lipogenesis
inhibiting the flux of TAG from the blood stream. This could explain the association between
increasing age and the increase in plasma TAG observed in both males and females  [34].
Insulin resistance also accompanies excess FFAs, and is likely to be induced by a decrease in
the activity  of the insulin receptor.  It  has also been proposed lipotoxic induced oxidative
stress could have a role to play in this phenomenon, as demonstrated by a recent experimental
study exposing cultured human hepatocytes to FA activated oxidative stress [35]. In addition,
this study found that FA exposure stimulated the production of the prothrombotic marker,
plasminogen activator inhibitor-1 (PAI-1). This is not surprising, as increased inflammation
is also a pathophysiological response to elevated FFAs. For instance, Pararasa et al. (2016)
reported fasting plasma saturated fatty acids (SFAs), monounsaturated fatty acids (MUFAs)
and polyunsaturated fatty acids (PUFAs) were significantly higher in healthy middle aged
men (aged 58±6.1 years) compared with their  younger  counterparts  (aged 24±3.8 years).
Furthermore,  pro-inflammatory  cytokines  tumour  necrosis  factor  (TNF)-α and  interleukin
(IL)-6 were significantly elevated in these middle aged subjects, while the anti-inflammatory
IL-10 was reduced [27]. The next section will explore the relationship between inflammation,
aging and fat metabolism in greater depth. 
Inflammaging
Aging  is  associated  with  concomitant  chronic  low  grade  systemic  inflammation.  This
phenomenon is referred to as inflammaging [36]. Inflammaging is considered a risk factor for
both morbidity and mortality in older people  [37], as it is thought the rise in inflammatory
markers,  such  as  C-reactive  protein  (CRP)  and  IL-6  are  associated  with  physiological
dysregulation and the onset of age-related disease. Stepanova et al. (2015) observed obesity
was associated with age-related chronic disease, with a trend for co-occurrence. Specifically,
the authors found obesity to be prevalent in 37% of individuals with one age-related chronic
disease  and  in  58%  of  individuals  with  two  or  more  age-related  chronic  diseases.
Additionally, the prevalence of hypercholesterolemia increased from 24% in healthy controls,
to 34 and 52% in individuals with one and two or more chronic diseases, respectively [38]. 
Several markers of inflammation are associated with the accumulation of visceral adipose
tissue  including,  the  pro-inflammatory  cytokines  IL-6,  TNF-α,  TFG-β1,  monocyte
chemotactic  protein-1  (MCP-1),  iNOS,  coagulation  factors,  fibrinogen,  PAI-1,  and  acute
phase proteins serum amyloid A (SAA) and CRP  [39-44]. These biomarkers have a broad
range of physiological roles in the promotion of inflammation (Figure 3). For example, MCP-
1 induces the migration of monocytes to the area [45], while the pro-inflammatory cytokine
IFN-γ  induces  monocyte  polarisation  to  M1 macrophages  [46].  This  is  accompanied  by
progressive lipid accumulation and foam-like cell formation within the adipose tissue  [47].
An increased M1:M2 ratio inflammatory profile is associated with the further release of pro-
inflammatory cytokines,  TNF-α, IL-1β, IL-6, and IL-12, in addition to an increase in the
expression  of  pattern  recognition  receptors,  such  as  TLR  [48].  Moreover,  elevated
mitochondrial  superoxide  generation,  and  significantly  reduced  plasma  glutathione  were
associated  with  this  inflammatory  profile  [27].  The  resulting  inflammation  has  been
associated  with  the  promotion  of  insulin  resistance,  mitochondrial  dysfunction,  ROS
accumulation and the pathogenesis of T2DM  [49]. Additionally, inflammation affects fatty
acid metabolism in a variety of ways. For example, Zhang et al. (2002) demonstrated TNF-α
promotes the lipolysis of TAG in human adipocytes via the activation of mitogen activated
protein  kinase  (MEK)  and  extracellular  signal  related  kinase  (ERK)  and  elevation  of
intracellular cAMP [50]. Moreover, TNF-α activation of the MEK1/2-ERK1/2 pathway has
been  implicated  in  the  phosphorylation  and  concomitant  increase  in  activity  of  HSL,
stimulating  lipolysis,  contributing  to  increased  hepatic  production  of  glucose  [51].  In
addition, TNF-α inhibits the maturation of adipocytes by selectively activating TNF receptor
1 [52]. 
Interestingly, it appears a bi-directional relationship exists between fatty acid metabolism and
the  immune  response,  as  FFAs can  modulate  the  inflammatory  response.  However,  it  is
important  to  note  FFAs exert  different  effects  on  the  inflammatory  status.  For  example,
Pararasa et al. (2016) demonstrated elevated palmitic acid (C16:0) was related to an increase
in TNF-α and mitochondrial superoxide generation, while high levels of the SFAs stearic acid
(C18:0) and lignoceric acid (C24:0) have been associated with reduced transforming growth
factor  (TGF)-β1 levels  [27].  Furthermore,  the PUFA punicic acid (C18:3 (n-5)) has been
observed  to  ameliorate  the  mitochondrial  dysfunction  and  insulin  resistance  associated
adipocyte TNF-α expression  [53]. Importantly, inflammation induced by aging and obesity
can be ameliorated by diet  [54,55]. For example, Bashir et al. (2016) demonstrated fish oil
supplementation resulted in a reduction in adiposity index, serum cholesterol, serum TAG
and  insulin  resistance  in  obese  insulin-resistant  mice  fed  a  high  fat  diet.  Moreover,  this
supplementation  resulted  in  a  reduction  in  M1 phenotype  markers,  while  M2 phenotype
markers increased in a dose-dependent manner [56]. In addition, fish oil has been observed to
reduce a range of inflammatory-related genes in humans, including the gene encoding for
matrix metalloprotease MMP9, which plays an important role in macrophage infiltration [33].
Gironés-Vilaplana  et  al.  (2014)  describe  several  Latin-American  fruits  that  exhibit  good
antioxidant  capacities,  and α-glucosidase and pancreatic  lipase inhibitory activities,  which
could  be  utilised  in  the  treatment  of  obesity  and  T2DM  [57].  Additionally,  it  has  been
demonstrated  inflammation  can  also  be  ameliorated  by  weight  loss.  For  instance,  Aron-
Wisnewsky et  al.  (2009)  reported  a  15% total  body weight  loss  3  months  post-bariatric
surgery, resulted in a 2-fold reduction in the M1:M2 ratio [58]. 
The Endocrine System: Age related Modulation and Obesity 
As outlined in figure 4, the endocrine system has a significant role to play in the regulation of
fatty acid metabolism[59]. For instance, hormones such as insulin and glucagon interact with
fatty acid metabolism to remove glucose from the plasma. Post prandial insulin secretion, not
only  induces  the  transportation  of  GLUT4  to  the  plasma  membrane,  but  increases  non
esterified fatty acids (NEFA) synthesis in addition to inhibiting lipolysis[60,61]. Conversely,
glucagon  stimulates  the  release  of  glucose,  decreases  NEFA  synthesis  and  upregulates
lipolysis to increase the concentration of plasma glucose[62]. These straightforward examples
provide an insight into how the endocrine system intersects with these metabolic systems.
However, hormone production diminishes with age[63], which has an inevitable impact on
fatty acid metabolism. In this section we will explore in detail some of the hormones that are
key regulators of fat metabolism and how they change with age and obesity.
Glucagon and the regulation of Acetyl CoA Carboxylase
NEFA synthesis  is  hormonally  regulated  at  the  irreversible  conversion  of  acetyl  CoA to
malonyl  CoA  by  acetyl  CoA  carboxylase[43].  Glucagon  perturbs  NEFA  synthesis  by
phosphorylating acetyl CoA carboxylase by cAMP-dependent protein kinase, which in turn
inactivates  the  enzyme,  while  insulin  activates  enzyme  activity  by  promoting  its
dephosphorylation[64].  Additionally,  it  has  been demonstrated  epinephrine  downregulates
acetyl CoA carboxylase activity[64]. However, it has been found in isolated hepatocytes from
rats,  the  ability  of  glucagon  to  stimulate  phosphorylase  activity  and  cAMP  generation
decreases with increasing age[65]. 
Lipolysis: Hormone Sensitive Lipase and Lipoprotein Lipase
Langin  et  al.  (2005)  determined  obesity  induced  a  60%  decline  in  HSL  expression  in
differentiated  human preadipocytes.  This  under-expression of  HSL may contribute  to  the
defect  in  lipolysis  often  observed in  obesity[66],  For  example,  insulin  inhibits  HSL, and
hence  lipolysis  via  the  activation  of  cAMP  phosphodiesterase;  increased  degradation  of
cAMP; and inhibition  of  cAMP dependent  protein  kinase.  Insulin  may also inhibit  HSL
independently of cAMP via the activation of protein phosphatase [67]. Conversely, glucagon;
epinephrine; and growth hormone (GH) enhance HSL activity and lipolysis[68]. 
The hydrolysis of TAG to FFA and glycerol by LPL is influenced by insulin. LPL activity in
adipose tissue is  greatest  following feeding, and lowest during fasting  [69], however,  the
effect  of  hormonal  interactions  appears  to  be  site  dependent.  For  instance,  it  has  been
demonstrated LPL activity is elevated by insulin in human adipose tissue, while a decrease is
observed in skeletal muscle [70,71]. Glucagon has been observed to elevate LPL activity in
rat myocardial tissue and human plasma  [72,73], and decrease LPL activity in rat adipose
tissue [74]. Additionally, Ricart-Jané et al. (2005) observed that chronic stress reduced LPL
activity  in  adipose tissue,  while  limb muscle,  myocardial,  adrenal,  plasma and total  LPL
activity increased. These findings suggest catecholamines also interact with LPL in a site
specific manner [75]. GH has also been observed to increase heart and skeletal muscle LPL
activity  [76]. Obesity has been associated with the elevation of insulin and glucagon, while
epinephrine and GH have observed to decline [77-79]. Moreover, aging has been associated
with significant reduction in both peak day and night secretion of GH  [80]. Furthermore,
Esler et al. (1995) reported aging is associated with a 40% decline in epinephrine secretion. It
is important to note the concomitant 20% reduction in plasma epinephrine clearance  [81].
From the perspective of aging the activity of LPL has been reported to reduce by as much as
55–60%[82,83]. This could in part be explained by the decline in physical activity with age,
as  Bey and Hamilton  describe  physical  inactivity  has  been observed to  decrease  heparin
releasable LPL activity by 90-95% in rats, with ambulatory activity accounting for ~95%.of
the variation between muscle fibres[84].
The HPA Axis
The hypothalamic-pituitary-adrenal (HPA) axis is affected by aging[85]. It has been shown
the HPA axis becomes increasingly hyper-responsive as a result of this metabolic change in
middle aged women[86]. Moreover, Roelfsema et al. (2012) observed that basal; pulsatile;
and  total  ACTH  secretion  was  1.4,  1.6  and  1.5  times  greater,  respectively  in  obese
premenopausal  women,  when  compared  to  their  normal  weight  counterparts.  However,
despite this increase in ACTH secretion, cortisol levels remained unaffected. This is thought
to be due to the significant decline in sensitivity to ACTH, in addition to a decrease in this
hormones efficacy [87]. Although it has been repeatedly observed that plasma cortisol is not
elevated  in  obese individuals,  there is  a greater  generation  of  cortisol  within the adipose
tissue, in addition to a rise in cortisol metabolite excretion [86-88]. This may be due to 11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD1), a bidirectional enzyme, which acts as a
reductase to convert cortisone to cortisol, and as a hydrolase for the reverse reaction  [89].
While obesity is related to impaired hepatic 11β-HSD1 activity, it has been demonstrated that
a 5.5kg/m2 increase in BMI reflected a 65% increase in adipose 11β-HSD1 activity in middle
aged females [86]. This increase in adipose 11β-HSD1 resulted in an elevated generation of
cortisol within the adipose tissue, which may play a role in the pathogenesis of obesity and
obesity related disease. 
In young healthy female humans, combined SFA, MUFA, and PUFA lipid–heparin infusion
inhibited ACTH and cortisol secretion  [90]. Another study demonstrated that by increasing
serum FFA, both ACTH and cortisol decreased initially, before increasing after 120 minutes.
Interestingly, the decline in ACTH was more pronounced in anorexic subjects, while cortisol
levels  were  unaffected  [91].  The  profile  of  the  FFA  may  be  an  important  factor  in
determining  the  response  of  the  HPA  axis,  as  determined  by  Katoh  et  al.  (2004),  who
demonstrated that the SFAs butyric acid (C4); caprylic acid (C8); lauric acid (C12); palmitic
acid  (C16);  and  stearic  acid  (C18)  significantly  reduced  the  CRH-induced  basal  ACTH
release, whereas the unsaturated fatty acids oleic acid (C18:1); linoleic acid (C18:2); linolenic
acid (C18:3); and arachidonic acid (C20:4) significantly increased CRH-induced basal ACTH
release  in  primary  cultured  rat  anterior  pituitary  cells  [92].  Interestingly,  a  bidirectional
relationship between the HPA axis and adipose tissue may exist. Arad et al. (2015) found that
elevated cortisol, due to ACTH injection, may result in the development of central obesity
and insulin resistance  [93]. However, as this study was conducted  in vitro, and using cells
from rodents, one needs to be cautious when considering the implications of these findings
for humans. It has also been demonstrated that aging affects the HPA axis. Basal morning
concentrations  of  dehydroepiandrosterone  (DHEA),  dehydroepiandrosterone  sulfate  (DS),
and  androstenedione  (A4)  were  significantly  reduced  in  older  females  aged  55-68 when
compared to younger females aged 20-35 years old, while cortisol levels were similar in both
groups.  In  addition,  the  decline  in  DHEA,  A4  and  DS  with  overnight  dexamethasone
treatment was more pronounced in the older group [94]. Intriguingly, it has been found that
DHEA replacement did not correct the alterations in meal fat partitioning and post absorptive
lipolysis associated with ageing, while testosterone only partially ameliorated these changes
[95].  
Adipocytokines: Leptin and Adiponectin
It  has  been observed,  that  increased  adiposity  may lead  to  elevated  levels  of  the  satiety
hormone leptin  [39]. Amouzou et al. (2016) report leptin increased from 14.7ng/ml in non-
obese controls to 44.6 and 44.7ng/ml, respectively in insulin sensitive and insulin resistant
obese post-menopausal women, aged between 50 and 64 years old [96]. Interestingly, males
appear to be more sensitive to the effects of leptin, and therefore exhibit lower concentrations
compared with females;  with leptin  concentration  and leptin  receptor  inversely correlated
with  serum  testosterone  [97].  The  increase  in  adiposity  observed  with  age  and  the
concomitant  elevation  in  leptin  and leptin  resistance,  has  been  associated  with  enhanced
lipolysis, reduced β-oxidation of fatty acids in addition to a reduction in glucose tolerance
[98].  Moreover,  it  has  been  postulated  that  leptin  resistance  may  contribute  to  the
pathogenesis of CVD [99]. In contrast, the adipocytokine adiponectin decreases as a result of
being obese  [39].  Adiponectin  promotes  glucose  utilisation  and fatty  acid  oxidation,  and
reduction  of  this  adipocytokine  is  associated  with  insulin  resistance  [100].  For  example,
Amouzou  et  al.  (2016)  reported  a  decrease  in  adiponectin  from 17.4ng/ml  in  non-obese
controls to 12.1 and 9.3ng/ml in insulin sensitive and insulin resistant obese post-menopausal
women, respectively  [96]. Kim et al (2015) suggests the inhibition of adiponectin amongst
the  obese  may  be  due  to,  obesity-induced  pro-inflammatory  cytokines  inducing  the
hypermethylation of compact chromatin structures in the adiponectin gene promoter by the
methyl  transfer  enzyme DNA methyltransferase  1 (DNMT1),  impeding the expression of
adiponectin  [101].  Interestingly,  inhibition  of  DNMT1  activity,  or  supplementation  with
adiponectin or adiponectin receptor ameliorated induced insulin resistance [101-103]. 
Mathematical Modeling of Lipid Metabolism
From our discussion of obesity, fatty acid metabolism and its interaction with aging, it is
apparent this is a complex system with many interacting biological components. Therefore,
studying these interactions is challenging. In recent years biological research has benefited
significantly  from  using  mathematical  modeling  to  help  improve  our  understanding  of
multifaceted biological systems (reviewed in[104-107]). This approach provides a flexible
framework which enables hypothesis exploration and enables the dynamics of a biological
system to be predicted.  Recently,  we used mathematical  modeling  to  explore how aging
impacts the biological mechanisms responsible for the regulation of whole-body cholesterol
metabolism[108-110], and to explore the impact of acute and chronic levels of cortisol on
brain aging[85]. This model could be extended to include some of the interactions between
fat metabolism and cortisol regulation discussed in this paper. More specific to fatty acid
metabolism, we also developed a mathematical model of microtubule growth and shrinkage
for differential actions of short chain fatty acids in the gut[111]. Other groups, have also used
mathematical modeling as conduit for understanding adipose tissue regulation. For instance,
Kim et al. (2008) developed a mathematical model of adipose tissue metabolism. The model
was able to simulate physiological responses from the different expression levels of lipases
and found that  during  epinephrine  infusion,  lipases  are  differentially  activated,  such that
DAG breakdown is approximately four times faster than triglyceride breakdown[112]. 
Expert commentary 
The world population is aging, and with a rise in the global population comes an increase in
the prevalence of age related diseases. Many of these diseases, such as CVD and T2DM are
impacted significantly by the dysregulation of fat metabolism. Overweight and obesity are
central to the disruption of fat metabolism, as it is the fundamental factor which provokes a
rise in plasma free fatty acids. Increased plasma free fatty acids coincide with a plethora of
metabolic changes which contribute to the pathophysiology of obesity and the eventual onset
of  disease.  The  aging  process  also  disrupts  the  physiological  systems  and  biological
mechanisms responsible for the regulation of fat metabolism. Specifically, there is significant
overlap between the immune aging/inflammaging and the disruption of fat metabolism. Age
related hormonal changes also disrupt fat metabolism, while there is a negative impact on
endocrine  systems,  such  as  the  HPA  axis  as  a  result  of  overweight/obesity.  It  is  also
important to acknowledge the increased level of crosstalk between physiological systems as a
result of aging and how it impacts the onset of disease. This is particularly relevant as the
global  population  continues  to  rise,  as  it  is  predicted  the prevalence  of  obesity  will  also
increase  across  all  age  groups  in  many  countries.  Excess  caloric  intake,  coupled  with  a
demographic change in favour of older people will pose a significant challenge to healthcare
in coming years. To date, public health strategies have failed to curb the increase in obesity,
thus it will require innovative and imaginative initiatives to stem this global crises. 
Five-Year View
 There will continue to be an increase in life expectancy 
 There will be a concomitant rise in the prevalence of obesity
 Public health strategies to deal with this crises remain to developed
 Health care systems will continue to see a rise in clinical conditions associated with 
obesity
 It will be increasingly recognized intrinsic aging must be considered in addition to 
excess caloric intake when investigating the pathophysiology of obesity
Key issues 
 Globally the population of the world is aging 
 The prevalence of obesity is on the increase 
 With an increase in obesity, there comes a increase in the metabolic condition which 
are associated with the dysregulation of fat metabolism
 Intrinsic aging also impacts fat metabolism
 Disturbances to fat metabolism may be related to the aging process as well as excess 
calorie intake
 There is a bidirectional relationship between fatty acid metabolism and inflammation 
 Accumulation of visceral adipose tissue with age is associated with inflammation.
 Dysfunction of the endocrine system significantly impacts fatty acid metabolism. 
Conclusions 
Experimental evidence firmly suggests the dysregulation of fat metabolism plays a role in the
development of metabolic conditions such CVD and T2DM. This dysregulation is at least
partly driven by the disruption of adipose tissue due to excess fat accumulation, as a result of
excess calorie intake. In addition, the aging process affects the biological mechanisms and
physiological  systems  responsible  for  the  homeostatic  maintenance  fat  metabolism.  It  is
important to consider the contribution of both diet and intrinsic aging when exploring the
metabolic complications that accompany obesity.
Figure 1 Adult population weight by age and gender. Weight category defined by BMI;
underweight  <18.5kg/m2,  normal  weight  18.5-25kg/m2,  overweight  25-30kg/m2,  obese 30-
40kg/m2, morbidly obese <40kg/m2. (Data from [113]).
Figure 2 Overview of fatty acid metabolism. Abbreviations: FFA, free fatty acids; HSL,
hormone sensitive lipase; LPL, lipoprotein lipase;  TAG, triacylglycerol;  VLDL, very low
density lipoprotein. Arrows represent flux or the action of an enzyme. The Greek symbol
theta represents utilisation of the metabolite.  
Figure  3  Hormonal  interactions  with  fatty  acid  metabolism. Abbreviations:  ATGL,
adipose triglyceride lipase; ATP, adenosine triphosphate;  DAG, diacylglycerol; FAS, fatty
acid synthase; FFA, free fatty acids; GH, growth hormone; HSL, hormone sensitive lipase;
LPL,  lipoprotein  lipase;  MAG,  monoacylglycerol;  MDH,  malate  dehydrogenase;  TAG,
triacylglycerol; TCA, tricarboxcylic acid. Arrows represent flux or the action of an enzyme.
The Greek symbol theta represents utilisation of the metabolite.
Figure  4  Role  of  increased  adiposity  in  the  promotion  of  an  inflammation,  and
pathogenesis  of  obesity-related  disease. Abbreviations:  FFA,  free  fatty  acids;  HSL,
hormone sensitive  lipase;  IFN-γ,  interferon-γ;  LPL,  lipoprotein  lipase;  MCP-1,  monocyte
chemotactic protein-1; ROS, reactive oxygen species; TAG, triacylglycerol; T2DM, type 2
diabetes mellitus; VLDL, very low density lipoprotein. Arrows represent flux or the action of
an enzyme/hormone. T shaped arrows represent inhibition.
